Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial (Q33421348)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

19

object named as

Axel Le Cesne

0 references

Sophie Piperno-Neumann

10

object named as

Sophie Piperno-Neumann

0 references

object named as

Benjamin Lacas

20

0 references

Sandrine Lavau-Denes

object named as

Sandrine Lavau-Denes

16

0 references

object named as

Nicolas Penel

4

0 references

Nicolas Isambert

9

object named as

Nicolas Isambert

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Florence Duffaud

21

object named as

Florence Duffaud

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

François Bertucci

12

object named as

François Bertucci

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cécile Guillemet

5

object named as

Cécile Guillemet

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christine Chevreau

3

object named as

Christine Chevreau

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Emmanuelle Bompas

13

object named as

Emmanuelle Bompas

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Patricia Pautier

1

object named as

Patricia Pautier

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Corinne Delcambre

6

object named as

Corinne Delcambre

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

18

object named as

Maud Toulmonde

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Olivier Collard

15

object named as

Olivier Collard

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Didier Cupissol

7

object named as

Didier Cupissol

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

French Sarcoma Group

22

object named as

French Sarcoma Group

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Patrick Soulié

17

object named as

Patrick Soulié

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

11

object named as

Antoine Thyss

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Anne Floquet

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Frédéric Selle

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jerôme Alexandre

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

18 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

457-464

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential gene expression in leiomyosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Trends in survival for patients with metastatic soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma G

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970070-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)70070-7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33421348&oldid=1835244006"